A detailed history of Royal Bank Of Canada transactions in Monte Rosa Therapeutics, Inc. stock. As of the latest transaction made, Royal Bank Of Canada holds 4,465 shares of GLUE stock, worth $37,327. This represents 0.0% of its overall portfolio holdings.

Number of Shares
4,465
Previous 4,187 6.64%
Holding current value
$37,327
Previous $15,000 53.33%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$3.59 - $6.97 $998 - $1,937
278 Added 6.64%
4,465 $23,000
Q2 2024

Aug 14, 2024

BUY
$3.38 - $7.86 $10,089 - $23,462
2,985 Added 248.34%
4,187 $15,000
Q1 2024

Nov 05, 2024

SELL
$4.26 - $8.46 $12,716 - $25,253
-2,985 Reduced 71.29%
1,202 $8,000
Q1 2024

May 15, 2024

SELL
$4.26 - $8.46 $42,242 - $83,889
-9,916 Reduced 89.19%
1,202 $8,000
Q4 2023

Feb 14, 2024

BUY
$2.5 - $5.93 $9,297 - $22,053
3,719 Added 50.26%
11,118 $62,000
Q3 2023

Nov 14, 2023

BUY
$4.78 - $7.22 $17,738 - $26,793
3,711 Added 100.62%
7,399 $35,000
Q2 2023

Aug 14, 2023

BUY
$4.53 - $8.4 $6,808 - $12,625
1,503 Added 68.79%
3,688 $25,000
Q1 2023

May 15, 2023

SELL
$5.95 - $8.21 $18,028 - $24,876
-3,030 Reduced 58.1%
2,185 $17,000
Q4 2022

Feb 14, 2023

BUY
$6.71 - $9.72 $29,295 - $42,437
4,366 Added 514.25%
5,215 $39,000
Q3 2022

Nov 14, 2022

BUY
$7.17 - $12.16 $1,340 - $2,273
187 Added 28.25%
849 $7,000
Q2 2022

Aug 15, 2022

SELL
$6.15 - $14.99 $9,919 - $24,178
-1,613 Reduced 70.9%
662 $7,000
Q1 2022

May 16, 2022

SELL
$10.36 - $20.41 $11,188 - $22,042
-1,080 Reduced 32.19%
2,275 $32,000
Q4 2021

Feb 14, 2022

BUY
$16.28 - $27.15 $33,797 - $56,363
2,076 Added 162.31%
3,355 $68,000
Q3 2021

Nov 15, 2021

BUY
$18.59 - $42.21 $23,776 - $53,986
1,279 New
1,279 $29,000

Others Institutions Holding GLUE

About Monte Rosa Therapeutics, Inc.


  • Ticker GLUE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,713,900
  • Market Cap $391M
  • Description
  • Monte Rosa Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. It develops an oral molecular glue degrader for GSPT1, a translational termination factor and degron-containing prot...
More about GLUE
Track This Portfolio

Track Royal Bank Of Canada Portfolio

Follow Royal Bank Of Canada and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

News

Stay updated on Royal Bank Of Canada with notifications on news.